Gracell Biotechnologies is based in San Diego. It has raised $520M in total funding. Latest round: IPO. Backed by AstraZeneca, Vivo Capital, Temasek.
Gracell Biotechnologies funding overview
Gracell Biotechnologies is based in San Diego. Gracell Biotechnologies has raised $520M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is an IPO announced in December 2023. The round record for Gracell Biotechnologies runs through 2023; nothing later has been disclosed. Investors on record include AstraZeneca, Vivo Capital, Temasek, OrbiMed, RA Capital Management, Adage Capital Partners LP and 13 others. 19 distinct backers are named across the disclosed rounds.
Gracell Biotechnologies at a glance
Total raised
$520M
Latest round
IPO
Latest round date
December 2023
Headquarters
San Diego
Notable investors
AstraZeneca, Vivo Capital, Temasek, OrbiMed, RA Capital Management, Adage Capital Partners LP, Lilly Asia Ventures, Janus Henderson Investors
Frequently asked about Gracell Biotechnologies funding
How much has Gracell Biotechnologies raised?
Gracell Biotechnologies has raised $520M in total disclosed funding across the rounds on record.
Who has invested in Gracell Biotechnologies?
AstraZeneca, Vivo Capital, Temasek, OrbiMed, RA Capital Management, Adage Capital Partners LP are named among the investors backing Gracell Biotechnologies.
What was the latest Gracell Biotechnologies funding round?
The most recent disclosed round is an IPO, announced in December 2023.
Where is Gracell Biotechnologies based?
Gracell Biotechnologies is based in San Diego.
When did Gracell Biotechnologies last raise?
The last disclosed Gracell Biotechnologies round closed in December 2023 at IPO.
Every Gracell Biotechnologies figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in San Diego at a similar stage.
